Equities research analysts predict that Enanta Pharmaceuticals Inc (NASDAQ:ENTA) will report sales of $30.01 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Enanta Pharmaceuticals’ earnings. The highest sales estimate is $30.51 million and the lowest is $29.51 million. Enanta Pharmaceuticals reported sales of $8.96 million during the same quarter last year, which would suggest a positive year over year growth rate of 234.9%. The firm is scheduled to announce its next earnings report on Monday, May 14th.
According to Zacks, analysts expect that Enanta Pharmaceuticals will report full-year sales of $30.01 million for the current year, with estimates ranging from $136.31 million to $140.71 million. For the next year, analysts anticipate that the business will report sales of $119.40 million per share. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Enanta Pharmaceuticals.
Several research analysts recently commented on ENTA shares. TheStreet upgraded Enanta Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Wednesday, December 13th. ValuEngine upgraded Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Zacks Investment Research upgraded Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $82.00 price target for the company in a research report on Monday, February 12th. BidaskClub lowered Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 10th. Finally, JPMorgan Chase & Co. lowered Enanta Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Thursday, February 8th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $57.40.
Enanta Pharmaceuticals (NASDAQ ENTA) traded down $0.03 on Friday, reaching $86.18. The company had a trading volume of 163,877 shares, compared to its average volume of 231,314. The stock has a market capitalization of $1,633.45, a price-to-earnings ratio of 49.83 and a beta of 1.10. Enanta Pharmaceuticals has a 12 month low of $28.11 and a 12 month high of $95.91.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.